Business
Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit
Merck on Thursday reported third-quarter earnings and revenue that topped estimates as it saw strong demand for its cancer immunotherapy Keytruda.
The drugmaker also narrowed its full-year profit outlook to reflect lower estimated tariff costs, among other factors. Shares of Merck closed flat on Thursday.
Sales of Keytruda topped $8 billion for the first time in a quarter, rising 10% from the same period a year ago. Revenue from the drug of $8.14 billion came in just slightly under the $8.24 billion analysts were expecting, according to StreetAccount estimates.
The results come as Merck slashes $3 billion in costs by the end of 2027, and prepares to offset revenue losses from the upcoming patent expiration of Keytruda in 2028.
The pharmaceutical giant now expects its 2025 adjusted earnings to come in between $8.93 and $8.98 per share. That compares with its previous outlook of $8.87 to $8.97.
Merck said that reflects several new items, including “lower estimated costs related to the impact of tariffs.” During the previous two quarters, the company included a $200 million estimated hit from tariffs that President Donald Trump has implemented to date, but not his planned pharmaceutical-specific levies. Merck did not disclose a new estimate for the cost of existing tariffs.
Merck said the guidance also reflects a benefit from an amended deal with AstraZeneca related to a pill for a specific genetic disorder, partially offset by costs tied to the company’s now-completed acquisition of Verona Pharma.
Merck expects revenue for the year to come in between $64.5 billion and $65 billion, narrowed on both ends from its previous guidance of $64.3 billion to $65.3 billion.
Here’s what Merck reported for the third quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:
- Earnings per share: $2.58 adjusted vs. $2.35 expected
- Revenue: $17.28 billion vs. $16.96 billion expected
The company posted net income of $5.79 billion, or $2.32 per share, for the quarter. That compares with net income of $3.16 billion, or $1.24 per share, for the year-earlier period.
Excluding acquisition and restructuring costs, Merck earned $2.58 per share for the third quarter.
Merck raked in $17.28 billion in revenue for the quarter, up 4% from the same period a year ago.
Merck continued to see trouble with China sales of Gardasil, a vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S.
In February, Merck announced a decision to halt shipments of Gardasil into China beginning that month. In July, CFO Caroline Litchfield said the company will not resume shipments to China through at least the end of 2025, noting that inventories remain high and demand is still soft.
Gardasil generated sales of $1.75 billion for the quarter, down 24% from the same period a year ago due to lower demand in China. Still, that was in line with what analysts were expecting, according to StreetAccount.
Investors are eager for additional updates on Gardasil’s presence in China and any details from Merck on potential drug pricing deals with Trump as part of his controversial “most favored nation” policy. Trump has so far inked agreements with Pfizer, AstraZeneca and EMD Serono, the largest fertility drug manufacturer in the world, that aim to make their medicines easier for Americans to access.
In an earnings call on Thursday, Merck CEO Rob Davis said the company shares the Trump administration’s goal of “decreasing patient out-of-pocket costs for our products in the U.S. while at the same time realizing greater prices for our medicines and vaccines in countries that have not been paying fair value for the innovation we provide.”
Merck is “actively engaged” with the administration to achieve those efforts.
Pharmaceutical, animal health sales
Merck’s pharmaceutical unit, which develops a wide range of drugs, booked $15.61 billion in revenue during the third quarter. That’s up 4% from the same period a year earlier.
The increase in Keytruda was driven by higher uptake of the drug for earlier-stage cancers and strong demand for the treatment for metastatic cancers, which spread to other parts of the body, the company said.
Meanwhile, Merck’s newer drug Winrevair, which is used to treat a rare, deadly lung condition, recorded $360 million in sales for the quarter. Analysts had expected the medication to bring in $413 million, according to StreetAccount estimates.
Winrevair’s growth largely reflects higher uptake in the U.S. But it was partially offset by the timing of distributor purchases of the drug and lower net pricing in the country, mainly due to changes to Medicare prescription drug plans.
Merck’s animal health division, which develops vaccines and medicines for dogs, cats and cattle, posted nearly $1.62 billion in sales, up 9% from the same period a year prior. The company said that mainly reflects higher demand for livestock products.
Correction: Sales for Merck’s animal health division were up 9% from the same period a year prior. An earlier version misstated the percentage.
Business
Tariff row: GTRI’s 3-step plan for India to protect its interests; key remarks on Russian oil – The Times of India
Global Trade Research Initiative (GTRI) has proposed a three-step strategy to safeguard India’s trade interests as discussions with the United States have stepped into the “advanced stage.” The agency has suggested measures like scaling back Russian oil imports, seeking trade parity and resuming talks on fair terms.
Here’s what GTRI’s 3 step plan says:
1. Halting Russian oil imports under sanctions
According to the think tank, the first move should be to stop importing oil from Russian companies currently under US sanctions, specifically Rosneft and Lukoil, which together account for 57% of Russia’s crude output. GTRI said that continuing to source crude from these firms exposes India to potential secondary sanctions that could extend and affect critical infrastructure. The note cautioned that more secondary sanctions might be far more damaging than tariffs, as they could disrupt SWIFT access, dollar payments and essential digital systems, potentially paralysing operations across refineries, ports and banks.
2. Removal of additional tariffs
Once such imports are halted, the advisory body recommends India to “press Washington to withdraw the punitive 25% “Russian oil” tariff.” Scrapping the tariff would cut India’s duty burden in the US by half, from 50% to 25%, and improve export competitiveness.These additional duties were introduced on July 31 which the US called a “Russian oil” tariff, accusing India of fueling Moscow’s war machine. Since then, India’s overall duty burden in the US market has climbed to 50%, coinciding with a noticeable drop in exports, down 37% between May and September.
3. Starting on fair terms
Only after tariffs return to normal levels, GTRI suggested to “restart trade negotiations…only on fair, balanced terms.”The organisation said India should push for tariff parity with its other major trade partners by targeting average duties of roughly 15% and securing duty-free access for priority sectors such as textiles, gems and jewellery, and pharmaceuticals.Commerce minister Piyush Goyal has signalled progress on a bilateral trade agreement with the United States, saying that the negotiations have reached an “advanced stage”. The development aligns with US President Donald Trump’s recent hint that a deal with India may be imminent.According to a TOI report, the proposed trade agreement could bring down US tariffs on Indian exports from 50% to 15%. In return, India is expected to scale back purchases of Russian oil and increase energy imports from the United States, along with fulfilling other commitments.
Business
‘Supply chain reliability’: Not Ukraine, Russia is now top sunflower oil supplier to India; how it happened – The Times of India
Even as Moscow’s crude dominates headlines, it’s not the only Russian oil flowing into India. Russia has now surpassed Ukraine to become India’s biggest supplier of sunflower oil, with shipments soaring twelvefold over the past four years, according to industry data cited by ET.
“Russia is the largest and most reliable source of sunflower oil in the world. We get advantage of supply chain reliability,” Sanjeev Asthana, CEO of Patanjali Foods and president of the Solvent Extractors’ Association of India (SEA) told ET.Back in 2021, Russian sunflower oil made up only around 10% of India’s total sunflower oil imports. By 2024, that share had jumped to 56%. India purchased 2.09 million tonnes of sunflower oil from Russia in the calendar year 2024, compared to just 175,000 tonnes in 2021.
How did the shift happen?
Before the war, Ukraine was India’s main supplier of sunflower oil, shipping nearly 90% of its agricultural exports through seaports. However, once the conflict began, Ukraine redirected most of its sunflower oil to European countries via road and rail after its access to Black Sea ports was blocked. Industry officials said this rerouting made shipments to India costlier and less predictable.Russia, meanwhile, continued exporting comfortably through its seaports, giving Indian buyers a more stable and assured supply route. “They were offering us competitive rates, which is the requirement of the Indian market,” said Sandip Bajoria, president of the International Association of Sunflower Oil.Exchanges between industry delegations from both countries in recent months have further strengthened the trade link.
India’s reliance on foreign oils
Sunflower oil is among India’s top three edible oils, yet less than 5% of what the country consumes is grown domestically. The country relies on imports to meet almost 60% of its cooking oil needs. Palm oil accounts for nearly half of that, followed by soyabean oil and sunflower oil. Farmers in the country scaled back sunflower cultivation in the 1990s, after cheaper imported oils began entering the market.Sunflower oil became popular once again in 2023 and 2024, when for the first time it became cheaper than palm oil, according to industry officials, cited by ET. The new pricing advantage helped Russian shipments narrow the market gap between sunflower oil and soyabean oil. “The share of sunflower oil was a distant third after soyabean oil. The Russian supplies have reduced this gap significantly,” Bajoria said.This turnaround may not hold through the year. Sunflower oil imports are expected to decline by about 13% because of a sharp price rise. “The overall imports of sunflower oil will decline this year as there is a premium of $150 per tonne on sunflower oil over the palm oil and soyabean oil,” Bajoria added. “However, the share of Russia will remain the same at around 55-60%.”In September, a delegation from SEA travelled to Russia to explore deeper trade cooperation.
Business
Banking, GST, Aadhaar And Pension Rules Change from November 1: Here’s What To Know
Starting November 1, 2025, several key financial and administrative changes will take effect across India, impacting banking, GST, Aadhaar, pensions, and more. These updates aim to simplify processes but may also introduce new charges if not followed in time. Here’s a simplified breakdown of what’s changing and how it affects you.

Banking – Multiple Nominees Allowed: Account holders can now add up to four nominees per account. You can assign specific percentage shares to each nominee.

A successive nominee feature ensures that if one nominee passes away, the next in line becomes active automatically. While not mandatory, banks must inform customers about this option. If a nominee dies, their share is automatically canceled.

GST – New Slab Structure: The GST system is being simplified. The 12% and 28% slabs are being removed. A two-slab system will replace the current four-tier structure. Luxury and sin goods will now attract a 40% tax rate.

SBI Card – New Charges on Education Payments: A 1% fee will apply to education-related payments made via third-party apps like MobiKwik or CRED using SBI Cards. Loading over ₹1,000 into digital wallets with an SBI Card will also incur a 1% charge.

Aadhaar – Update Fee Changes: Children’s biometric updates are now free for one year (previously ₹125). For adults, demographic updates (name, address, mobile) will cost ₹75 while biometric updates remain at ₹125.

Updates can now be done online without uploading documents, making the process faster and easier.

Pension – Life Certificate Deadline: Central and state pensioners must submit their life certificates by November 30 to avoid payment disruptions.

Those switching from NPS to UPS must complete the transition within this month.

PNB Locker Charges Reduced: Punjab National Bank will revise its locker rental charges based on size and category. New rates will be published on the bank’s website in November and implemented 30 days after notification.
-
Politics7 days agoTrump slams ‘dirty’ Canada despite withdrawal of Reagan ad
-
Tech1 week agoDefect passivation strategy sets new performance benchmark for Sb₂S₃ solar cells
-
Business1 week agoJLR shutdown after cyber hack drives slump in UK car production
-
Tech1 week agoTurning pollution into clean fuel with stable methane production from carbon dioxide
-
Sports1 week agoAlleged mob ties in NBA scandal recall La Cosa Nostra’s long shadow over sports
-
Business1 week agoAssaults on rail network more than triple in 10 years
-
Business1 week ago47.7% of Mutual Fund Assets Now Invested Directly, ICRA Analytics Says
-
Sports1 week agoNBA legend Chauncey Billups, Heat’s Terry Rozier arrested as part of FBI gambling probe
